KPNA3 Antibody

Western Blot: KPNA3 Antibody [NB100-81650] -

Western Blot: KPNA3 Antibody [NB100-81650] - DZNep suppressed MPNST724 xenograft tumor initiation & growthin vivo. (A) MPNST724 xenograft tumor groups treated with vehicle only, 1 mg/kg DZNep, or 5 mg/kg DZNep 13 weeks after subcutaneous injection (n = 9 mice per group). (B) Growth curves of tumors treated with vehicle only, 1 mg/kg DZNep, or 5 mg/kg DZNep over a period of 13 weeks. Mean ± SD values are shown; *p < 0.05, Student t test. (C) Western blot analyses of EZH2, KPNB1, & actin in tumor MPNST samples treated with vehicle only, 1 mg/kg DZNep, or 5 mg/kg DZNep. Image collected & cropped by CiteAb from the following publication (http://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-015-0…), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: KPNA3 Antibody [NB100-81650] -

Western Blot: KPNA3 Antibody [NB100-81650] - DZNep inhibited EZH2/miR-30d/KPNB1 signaling in MPNST cells. (A) Western blot analyses of EZH2, cleaved PARP (cPARP), KPNB1, & GAPDH (loading control) in MPNST724 & S462 cells treated with DZNep at increasing concentrations for 48 hours. (B) qRT-PCR analyses of miR-30d expression in MPNST724 & S462 cells treated with DZNep for 96 hours. miR-30d expression was normalized to SNORD47. Mean ± SD values are shown (n = 3); *p < 0.05, Student t test. (C) Promoter activity assay showed that DZNep treatment increased miR-30d promoter activity in S462 cells. Mean ± SD values are shown (n = 3); *p < 0.05; Student t test. (D) Luciferase reporter assay showed that DZNep treatment inhibited miR-30d target reporter activity in S462 cells. Mean ± SD values are shown (n = 3); **p < 0.01, Student t test. (E) Luciferase reporter assay indicated that DZNep treatment inhibited wild-type (WT) KPNB1 3’UTR reporter activity but not mutant (MT) KPNB1 3’UTR reporter activity in S462 cells. Mean ± SD values are shown (n = 3); *p < 0.05, Student t test. Image collected & cropped by CiteAb from the following publication (http://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-015-0…), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: KPNA3 Antibody [NB100-81650] -

Western Blot: KPNA3 Antibody [NB100-81650] - EZH2-regulated miR-30a targeted KPNB1 in MPNST cells. (A) Putative miR-30a & miR-30d target site in the wild-type KPNB1 3’UTR region. (B) qRT-PCR analyses of miR-30a in MPNST724 & S462 cells transfected with a negative control or EZH2 siRNA. miR-30a expression was normalized to SNORD47. Data are shown as mean ± SD (n = 3); *p < 0.05, Student t test. (C) qRT-PCR analyses of miR-30a in S462 & MPNST724 cells treated with DZNep for 96 hours. miR-30d expression was normalized to SNORD47. Mean ± SD values are shown (n = 3); *p < 0.05, Student t test. (D) Western blot analyses of KPNB1 & actin in S462 & MPNST724 cells transfected with a negative control (Ctl) or miR-30a (30a) mimics. (E) Luciferase reporter assay showed that miR-30a inhibited wild-type (WT) KPNB1 3’UTR reporter activity but not mutant (MT) KPNB1 3’UTR reporter activity in S462 cells. Mean ± SD values are shown (n = 3); *p < 0.05, Student t test. (F) qRT-PCR analyses of miR-30a expression in normal Schwann cells (NSC) & multiple MPNST cell lines (MPNST724, S462, STS26T, MPNST624, T265, & ST88-14). Image collected & cropped by CiteAb from the following publication (http://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-015-0…), licensed under a CC-BY license. Not internally tested by Novus Biologicals.